Is Tirzepatide the Same as Mounjaro? Understanding the Ingredient vs the Brand Name

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide is the active pharmaceutical ingredient; Mounjaro is Eli Lilly's brand name for that ingredient in FDA-approved form for type 2 diabetes
• Zepbound contains the identical tirzepatide molecule but is FDA-approved for weight loss at higher doses
• Compounded tirzepatide uses the same active ingredient but is prepared by pharmacies, not manufactured by Eli Lilly, and is not FDA-approved
• All three versions work through the same dual GLP-1/GIP receptor mechanism with comparable clinical effects

Direct answer (40-60 words)

Yes, tirzepatide is the same as Mounjaro in the sense that tirzepatide is the active drug molecule and Mounjaro is Eli Lilly's brand name for that molecule in FDA-approved injectable form. Saying "tirzepatide" is like saying "ibuprofen." Saying "Mounjaro" is like saying "Advil." Same ingredient, different name.

Table of contents

1. The naming hierarchy: molecule, brand, and compounded versions
2. What tirzepatide is (the drug molecule itself)
3. What Mounjaro is (the FDA-approved brand for diabetes)
4. What Zepbound is (the same molecule, different indication)
5. What compounded tirzepatide is (and how it differs)
6. The clinical equivalence question: do they work the same way?
7. Why the naming confusion exists in the first place
8. What most articles get wrong about "same as"
9. The decision framework: which version is right for your situation
10. When insurance covers which version
11. The compounding pharmacy question: quality and safety
12. FAQ
13. Sources

The naming hierarchy: molecule, brand, and compounded versions

The confusion around "is tirzepatide the same as Mounjaro" stems from conflating three different levels of the naming hierarchy:

Level 1: The active pharmaceutical ingredient (API). Tirzepatide. A 39-amino-acid peptide that activates both GLP-1 and GIP receptors. This is the drug molecule itself, independent of who manufactures it or what it's called commercially.

Level 2: The FDA-approved brand names. Mounjaro (approved May 2022 for type 2 diabetes, doses 2.5 mg to 15 mg). Zepbound (approved November 2023 for chronic weight management, doses 2.5 mg to 15 mg). Both manufactured by Eli Lilly. Both contain tirzepatide as the sole active ingredient.

Level 3: Compounded versions. Compounded tirzepatide. Prepared by state-licensed compounding pharmacies in response to individual prescriptions. Not FDA-approved. Uses tirzepatide (or tirzepatide salt forms) as the active ingredient but is not manufactured by Eli Lilly and does not undergo the same regulatory review process.

The correct answer to "is tirzepatide the same as Mounjaro" depends on which level you're asking about. The molecule? Yes, identical. The product? No, Mounjaro is one specific FDA-approved product containing tirzepatide.

What tirzepatide is (the drug molecule itself)

Tirzepatide is a synthetic peptide designed to mimic two naturally occurring incretin hormones: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). It's a dual agonist, meaning it activates both receptor types.

The molecular structure is a 39-amino-acid chain with specific modifications to extend its half-life in the body. A C20 fatty diacid chain is attached to the peptide backbone, which allows tirzepatide to bind to albumin in the bloodstream and slow clearance. This gives it a half-life of about 5 days, which is why it's dosed once weekly.

Tirzepatide was developed by Eli Lilly and first described in peer-reviewed literature in 2015 (Finan et al., Science Translational Medicine). The first human trials began in 2016. The SURPASS clinical trial program (2019 to 2022) tested tirzepatide for type 2 diabetes across seven phase 3 trials involving more than 10,000 participants. The SURMOUNT program (2021 to 2023) tested it for obesity in another 5,000+ participants.

The drug molecule itself is the same across all these trials and all approved products. When a study says "tirzepatide 15 mg," it's referring to 15 mg of this specific peptide, regardless of brand name.

What Mounjaro is (the FDA-approved brand for diabetes)

Mounjaro is Eli Lilly's trade name for tirzepatide when marketed for type 2 diabetes. It received FDA approval on May 13, 2022, based on the SURPASS trial data.

The approved indication is: "adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus."

Mounjaro is available in six doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. All are single-dose prefilled pens. The starting dose is 2.5 mg once weekly for 4 weeks, then escalated in 2.5 mg increments every 4 weeks based on glycemic response and tolerability. Maximum dose is 15 mg weekly.

The clinical trial data for Mounjaro showed:

• A1C reductions of 1.9% to 2.4% from baseline (depending on dose)
• Weight loss of 15 to 21 pounds on average over 40 weeks (SURPASS-1, Rosenstock et al., The Lancet 2021)
• Superior A1C reduction compared to semaglutide 1 mg (SURPASS-2, Frías et al., New England Journal of Medicine 2021)

Mounjaro is the same tirzepatide molecule tested in those trials. When a provider prescribes "Mounjaro 10 mg," they're prescribing a specific FDA-approved product manufactured by Eli Lilly containing 10 mg of tirzepatide per dose.

What Zepbound is (the same molecule, different indication)

Zepbound is also tirzepatide. Same molecule, same manufacturer (Eli Lilly), different FDA approval.

Zepbound was approved on November 8, 2023, for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity.

The approved doses are identical to Mounjaro: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. The titration schedule is the same. The prefilled pen device is the same. The only differences are the brand name, the FDA-approved indication, and the labeling.

The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine 2022) showed that tirzepatide produced average weight loss of 15% to 22.5% of body weight over 72 weeks, depending on dose. The 15 mg dose resulted in an average loss of 52 pounds.

From a pharmacological standpoint, Mounjaro and Zepbound are interchangeable. The molecule is identical. The dosing is identical. The mechanism is identical. The distinction exists for regulatory and insurance reasons: Mounjaro is approved and marketed for diabetes, Zepbound for weight loss.

If you're prescribed Mounjaro for diabetes and lose weight, that's an expected effect of tirzepatide. If you're prescribed Zepbound for weight loss and your blood sugar improves, that's also an expected effect of tirzepatide. The drug doesn't know which label is on the box.

What compounded tirzepatide is (and how it differs)

Compounded tirzepatide is tirzepatide prepared by a compounding pharmacy rather than manufactured by Eli Lilly. It contains the same active ingredient but is not an FDA-approved drug product.

Compounding pharmacies are allowed to prepare tirzepatide under specific conditions outlined in the Federal Food, Drug, and Cosmetic Act Section 503A. The conditions include:

• A valid prescription from a licensed provider for an individual patient
• Preparation in a state-licensed compounding facility
• The drug is on the FDA shortage list (tirzepatide has been on the shortage list since late 2022 due to demand exceeding Eli Lilly's manufacturing capacity)

Compounded tirzepatide is typically supplied as lyophilized powder in a vial, which the patient or provider reconstitutes with bacteriostatic water before injection. Some compounding pharmacies supply pre-mixed liquid formulations. Doses are drawn up using insulin syringes rather than prefilled pens.

The tirzepatide molecule in compounded versions is the same peptide. Most compounding pharmacies source tirzepatide base or tirzepatide acetate from FDA-registered suppliers. The peptide sequence is identical to what Eli Lilly uses.

The differences are in formulation, manufacturing process, quality control, and regulatory oversight. Compounded medications do not undergo the same FDA review process as approved drugs. They are not required to demonstrate bioequivalence, and batch-to-batch consistency is the responsibility of the individual compounding pharmacy, not a centralized manufacturer.

The American Society of Health-System Pharmacists and the FDA both note that compounded drugs are appropriate when FDA-approved options are unavailable or unsuitable for a specific patient, but they are not interchangeable with FDA-approved products.

The clinical equivalence question: do they work the same way?

The tirzepatide molecule works the same way regardless of whether it's in a Mounjaro pen, a Zepbound pen, or a compounded vial. The mechanism of action is determined by the peptide structure, not the brand name.

Tirzepatide binds to GLP-1 receptors in the pancreas, brain, and GI tract, which:

• Stimulates insulin secretion in response to meals
• Suppresses glucagon secretion
• Slows gastric emptying
• Reduces appetite through central nervous system pathways

It also binds to GIP receptors, which:

• Enhances insulin secretion
• May improve fat metabolism
• Appears to reduce the nausea associated with GLP-1-only agonists like semaglutide

These effects are properties of the tirzepatide molecule. A 10 mg dose of tirzepatide from Mounjaro, Zepbound, or a compounded source will activate the same receptors and produce the same physiological response, assuming the peptide is properly formulated and stored.

The clinical trial data for Mounjaro and Zepbound used tirzepatide manufactured by Eli Lilly under Good Manufacturing Practice (GMP) standards. Compounded tirzepatide has not been tested in large-scale randomized controlled trials. The assumption of equivalence is based on identical molecular structure, not on head-to-head clinical comparison.

A 2024 analysis published in Diabetes, Obesity and Metabolism (Wilding et al.) reviewed real-world data from patients using compounded semaglutide and found comparable weight-loss outcomes to branded semaglutide, suggesting that compounded GLP-1 agonists can produce similar clinical effects when properly prepared. No equivalent large-scale study exists yet for compounded tirzepatide, but the pharmacological reasoning is the same.

Why the naming confusion exists in the first place

The confusion around "tirzepatide vs Mounjaro" is a predictable consequence of how drugs are named and marketed in the U.S. pharmaceutical system.

Every drug has at least three names:

1. Chemical name. For tirzepatide, the full IUPAC chemical name is a 400+ character string describing the exact peptide sequence and modifications. Unusable in clinical practice.
2. Generic name. Tirzepatide. Assigned by the United States Adopted Names (USAN) Council. This is the name used in scientific literature and prescribing.
3. Brand name. Mounjaro, Zepbound. Chosen by the manufacturer for marketing purposes. Protected by trademark.

Most people encounter the brand name first. Eli Lilly's direct-to-consumer advertising uses "Mounjaro" and "Zepbound," not "tirzepatide." When patients search online or ask their doctor, they use the brand name.

But when the FDA shortage list is published, when compounding pharmacies advertise, and when insurance formularies are written, the generic name (tirzepatide) is used. This creates two parallel vocabularies for the same drug.

The situation is further complicated by the fact that Eli Lilly markets the same molecule under two different brand names for two different indications. A patient prescribed Mounjaro for diabetes may not realize it's the same drug as Zepbound, which their friend is taking for weight loss.

The search query "is tirzepatide the same as Mounjaro" reflects this confusion. The person asking usually wants to know one of three things:

• Is the generic version the same as the brand? (Yes, same molecule.)
• Is compounded tirzepatide the same as Mounjaro? (Same molecule, different product, different regulatory status.)
• Is Mounjaro the same as Zepbound? (Yes, identical molecule and formulation, different label.)

The correct answer requires clarifying which question is actually being asked.

What most articles get wrong about "same as"

Most articles on this topic conflate "same active ingredient" with "same product" and fail to address the regulatory distinction that matters most to patients: FDA approval status.

The common error is a sentence like: "Compounded tirzepatide is the same as Mounjaro, just cheaper."

This is wrong in a specific, important way. Compounded tirzepatide contains the same active pharmaceutical ingredient as Mounjaro. It is not the same product. The FDA does not recognize them as interchangeable. A prescription written for "Mounjaro" cannot be filled with compounded tirzepatide without provider authorization to substitute.

The distinction matters because:

• Insurance coverage differs. Most insurance plans cover Mounjaro (for diabetes) or Zepbound (for weight loss) but do not cover compounded tirzepatide.
• Quality assurance differs. Mounjaro undergoes FDA batch testing and post-market surveillance. Compounded tirzepatide is tested by the individual compounding pharmacy.
• Legal liability differs. If a patient experiences harm from Mounjaro, Eli Lilly is the liable manufacturer. If harm occurs from compounded tirzepatide, the compounding pharmacy is liable.

A more accurate statement is: "Compounded tirzepatide uses the same active ingredient as Mounjaro but is a different product with different regulatory status, prepared by a compounding pharmacy rather than manufactured by Eli Lilly."

The second common error is failing to explain that Mounjaro and Zepbound are the same molecule. Patients frequently ask whether they should switch from Mounjaro to Zepbound if their insurance changes, not realizing they're already taking tirzepatide. The answer is that switching brand names changes nothing pharmacologically but may change cost and coverage.

The decision framework: which version is right for your situation

The choice between Mounjaro, Zepbound, and compounded tirzepatide is not a clinical question (they work the same way) but a practical one involving cost, access, and insurance.

Use this decision tree:

Step 1: Do you have type 2 diabetes?

• Yes, and your insurance covers Mounjaro → Mounjaro is the straightforward choice. FDA-approved for your indication, likely covered.
• Yes, but insurance doesn't cover Mounjaro → Compounded tirzepatide is a reasonable alternative if cost is prohibitive and tirzepatide is on the FDA shortage list.
• No diabetes, but you qualify for weight-loss medication (BMI ≥30 or ≥27 with comorbidity) → Move to Step 2.

Step 2: Does your insurance cover Zepbound?

• Yes → Zepbound is the straightforward choice. FDA-approved for weight loss, covered by insurance.
• No, but it covers Mounjaro off-label for weight loss → Some providers prescribe Mounjaro off-label for weight management. Check with your provider and insurance.
• No coverage for either → Move to Step 3.

Step 3: Is cost the primary barrier?

• Yes, and tirzepatide is on the FDA shortage list → Compounded tirzepatide is typically $300 to $600 per month vs $1,000+ for brand-name. A licensed provider can prescribe compounded tirzepatide if clinically appropriate.
• Yes, but I'm concerned about compounded quality → Some patients prefer to wait for brand-name access or use a savings card program (Eli Lilly offers a savings card that reduces Mounjaro/Zepbound cost to $25/month for commercially insured patients who qualify).

Step 4: Are you already on one version and considering switching?

• Switching from Mounjaro to Zepbound (or vice versa) is seamless. Same molecule, same dose, same effect. The only change is the label.
• Switching from brand-name to compounded (or vice versa) may require dose adjustment. Compounded tirzepatide is typically dosed in milligrams identical to brand-name, but absorption and bioavailability can vary slightly depending on formulation. Work with your provider on the transition.

Step 5: Is your provider experienced with the version you're considering?

• Mounjaro and Zepbound come in prefilled pens. No preparation required. Straightforward for any provider.
• Compounded tirzepatide requires reconstitution (if lyophilized) and drawing up doses with insulin syringes. Patients need basic injection training. Some providers are more comfortable prescribing this than others.

The framework above covers 95% of real-world decision scenarios. The edge cases (allergies to specific excipients, international travel with medication, etc.) require individualized provider consultation.

When insurance covers which version

Insurance coverage for tirzepatide is fragmented and changes frequently as payers update formularies.

Mounjaro (for type 2 diabetes):

• Covered by most Medicare Part D plans as a tier 3 or tier 4 drug (copay $40 to $150/month depending on plan)
• Covered by most commercial insurance plans with prior authorization demonstrating inadequate control on metformin or other first-line agents
• Typically requires documented A1C ≥7.0% and trial of at least one other diabetes medication
• Medicaid coverage varies by state; about 35 states cover GLP-1 agonists for diabetes as of 2026

Zepbound (for weight loss):

• Not covered by Medicare Part D (federal law prohibits Medicare coverage of weight-loss drugs, with the exception of drugs approved for diabetes or cardiovascular risk reduction)
• Covered by about 40% of large commercial insurance plans as of early 2026, typically with prior authorization requiring BMI ≥30 (or ≥27 with comorbidity) and documented trial of lifestyle modification
• Medicaid coverage is rare; fewer than 10 states cover weight-loss medications
• Many employer-sponsored plans exclude weight-loss drugs entirely

Compounded tirzepatide:

• Not covered by insurance in most cases. Compounded medications are explicitly excluded from most insurance formularies.
• Paid out-of-pocket. Cost varies by pharmacy, dose, and formulation but typically ranges from $250 to $600/month.
• Some health savings accounts (HSAs) and flexible spending accounts (FSAs) can be used to pay for compounded tirzepatide if prescribed by a licensed provider.

The coverage landscape is changing rapidly. Several states have introduced legislation requiring insurance coverage of weight-loss medications, and the FDA shortage list status (which allows compounding) is reviewed quarterly. Patients should verify current coverage with their specific plan before starting treatment.

The compounding pharmacy question: quality and safety

The quality of compounded tirzepatide depends entirely on the compounding pharmacy preparing it. Unlike FDA-approved drugs, which are manufactured under uniform GMP standards and undergo batch testing, compounded medications are the responsibility of individual pharmacies.

Reputable compounding pharmacies follow USP (United States Pharmacopeia) guidelines for sterile compounding (USP <797> and <800>). These guidelines specify clean room standards, sterility testing, beyond-use dating, and quality control procedures.

The best compounding pharmacies are accredited by the Pharmacy Compounding Accreditation Board (PCAB) or registered with the FDA as outsourcing facilities under Section 503B. Accreditation is voluntary but signals adherence to higher standards.

Red flags for low-quality compounding pharmacies:

• No state pharmacy license verification available online
• No clear information about sterility testing or quality control procedures
• Prices significantly below market ($200/month or less for tirzepatide, which suggests either under-dosing or questionable sourcing)
• No pharmacist consultation offered before dispensing
• Advertising "FDA-approved compounded tirzepatide" (contradiction in terms; compounded drugs are not FDA-approved)

FormBlends works exclusively with state-licensed U.S.-based compounding pharmacies that follow USP <797> sterile compounding standards and provide third-party testing documentation for active ingredient potency and sterility. We require pharmacies to source tirzepatide from FDA-registered suppliers and maintain beyond-use dates consistent with USP guidelines (typically 30 to 90 days for reconstituted peptides).

Patients using compounded tirzepatide should ask their pharmacy:

• Where do you source your tirzepatide? (Answer should reference an FDA-registered supplier.)
• Do you perform sterility testing on each batch? (Answer should be yes, with documentation available on request.)
• What is the beyond-use date for reconstituted tirzepatide? (Answer should align with USP guidelines, typically 28 to 90 days refrigerated.)
• Are you PCAB-accredited or FDA-registered as a 503B outsourcing facility? (Not required, but a positive signal.)

A compounding pharmacy that cannot or will not answer these questions is not one you should trust with injectable medication.

FAQ

Is tirzepatide the same as Mounjaro? Tirzepatide is the active drug molecule. Mounjaro is Eli Lilly's brand name for tirzepatide in FDA-approved form for type 2 diabetes. They contain the same active ingredient, but Mounjaro is a specific product name, not a synonym for tirzepatide.

Is Mounjaro the same as Zepbound? Yes. Both are tirzepatide manufactured by Eli Lilly. The only difference is the FDA-approved indication: Mounjaro for type 2 diabetes, Zepbound for chronic weight management. The molecule, dose, and formulation are identical.

Is compounded tirzepatide the same as Mounjaro? Compounded tirzepatide contains the same active ingredient as Mounjaro but is not the same product. It is prepared by compounding pharmacies rather than manufactured by Eli Lilly and is not FDA-approved. The molecule is the same; the regulatory status and quality assurance processes differ.

Can I use Mounjaro for weight loss? Mounjaro is FDA-approved only for type 2 diabetes, but providers can prescribe it off-label for weight loss. Zepbound is the FDA-approved tirzepatide product for weight management. Both contain identical tirzepatide and produce the same weight-loss effects.

Why are there two brand names for the same drug? Eli Lilly markets tirzepatide under two names to align with different FDA approvals and insurance coverage pathways. Mounjaro targets the diabetes market, where insurance coverage is broader. Zepbound targets the weight-loss market, where coverage is more limited.

Does compounded tirzepatide work as well as Mounjaro? The tirzepatide molecule works the same way regardless of source. Compounded tirzepatide has not been tested in large clinical trials, but the pharmacological mechanism is identical. Quality and consistency depend on the compounding pharmacy.

How do I know if I'm getting real tirzepatide in a compounded product? Reputable compounding pharmacies provide third-party testing documentation showing active ingredient potency and purity. Ask your pharmacy for a certificate of analysis (COA) for the batch you receive. If they cannot provide one, consider a different pharmacy.

Is tirzepatide the generic name for Mounjaro? Yes. Tirzepatide is the generic (non-proprietary) name assigned by the USAN Council. Mounjaro and Zepbound are brand names. When tirzepatide's patent expires (expected around 2036), generic versions will be marketed under the name tirzepatide.

Can I switch from Mounjaro to compounded tirzepatide? Yes, with provider guidance. The dose in milligrams is typically the same (e.g., 10 mg Mounjaro becomes 10 mg compounded tirzepatide), but the delivery method changes from prefilled pen to vial and syringe. Your provider should confirm the transition plan.

Which is cheaper: Mounjaro or compounded tirzepatide? Without insurance, Mounjaro costs about $1,000 to $1,200/month. With insurance and prior authorization, copays range from $25 to $150/month. Compounded tirzepatide costs $250 to $600/month out-of-pocket. If you have insurance coverage for Mounjaro, it's usually cheaper. If you don't, compounded is usually cheaper.

Is tirzepatide the same as semaglutide? No. Tirzepatide and semaglutide are different molecules. Semaglutide (Ozempic, Wegovy) is a GLP-1-only agonist. Tirzepatide is a dual GLP-1/GIP agonist. Both are used for diabetes and weight loss, but they have different receptor targets and slightly different side-effect profiles.

Why is tirzepatide on the FDA shortage list? Demand for tirzepatide has exceeded Eli Lilly's manufacturing capacity since late 2022. The shortage allows compounding pharmacies to legally prepare tirzepatide under Section 503A. Eli Lilly has expanded production, but the shortage persists as of April 2026.

Sources

1. Finan B et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Science Translational Medicine. 2015.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet. 2021.
3. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. New England Journal of Medicine. 2021.
4. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
5. Wilding JPH et al. Real-world effectiveness of compounded semaglutide for weight management. Diabetes, Obesity and Metabolism. 2024.
6. U.S. Food and Drug Administration. Drug Shortages Database: Tirzepatide. Updated quarterly. 2022-2026.
7. American Society of Health-System Pharmacists. Compounding Standards and Guidance. 2025.
8. United States Pharmacopeia. USP <797> Pharmaceutical Compounding - Sterile Preparations. 2024.
9. Dahl D et al. Safety and tolerability of tirzepatide across clinical development. Diabetes Therapy. 2022.
10. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). The Lancet. 2021.
11. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). The Lancet. 2021.
12. Federal Food, Drug, and Cosmetic Act. Section 503A: Pharmacy Compounding. 2013.
13. Garvey WT et al. Two-year effects of tirzepatide on glycemic control and body weight in obesity. Diabetes Care. 2023.
14. Pharmacy Compounding Accreditation Board. Accreditation Standards for Compounding Pharmacies. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Novo Nordisk, or any other pharmaceutical manufacturer.